Top Regimens by Diagnostic Group. April July 2012

Size: px
Start display at page:

Download "Top Regimens by Diagnostic Group. April July 2012"

Transcription

1 Top Regimens by Diagnostic Group April July 2012

2 Introduction The Top Regimens by Diagnostic Group report provides an overview of the most frequently administered regimens for major tumour sites. Within the report, there may be some records present where the diagnosis does not match the treatment recorded. This report reflects how data has been submitted to CIU. Oral chemotherapy may be under-represented, particularly for haematological groups such as myeloma.

3 Report Timeframe This report excludes activity for patients under the age of 16 at the time of starting a regimen. Only activity considered to be In Year is included. The recency of activity is derived from all populated date fields. Activity is considered to be In Year if it occurs on or after 1st April 2012.

4 Definition of Terms The following terms are used in this report: Number of Patients The number of unique patients with a primary diagnosis recorded that matches the relevant diagnostic group. Unique patients are identified by NHS number and postcode. A patient that receives chemotherapy treatment for multiple diagnoses in different diagnostic groupings and within the reporting period specified will be counted more than once.

5 Definition of Terms The following terms are used in this report: Number of First Cycles The number of patients with a primary diagnosis matching the relevant diagnostic group that have started a cycle of chemotherapy with a recognised regimen grouping. Patients starting multiple different regimens will be counted once in each regimen group. Total Cycles The aggregate total number of cycles delivered of the specified regimen to all patients with a primary diagnosis matching the relevant diagnostic group. This will include first cycles.

6 Definition of Terms The following terms are used in this report: All submitting trusts aggregated The total aggregated activity for all NHS hospital trusts that have submitted data at the time the report was produced. Coverage across diagnostic groups will vary as not all of the trusts are submitting data for all diagnostic groups at the time the report was produced.

7 Number of Patients by Diagnostic Group. Brain/CNS 414 (2%) Head and Neck 405 (2%) Other haematology 284 (1%) Other 1376 (5%) Leukaemia 772 (3%) Myeloma 890 (4%) Breast 6062 (24%) Gynae 1881 (7%) Upper GI 2071 (8%) Urology 2139 (9%) Lower GI 3734 (15%) Lymphoma 2172 (9%) Lung 2845 (11%)

8 Number of Patients by Diagnostic Group.

9 Number of Patients by Diagnostic Group. Prim ary Diagnosis Sub Group Num ber of Patients (All subm itting trusts aggregated) Leukaemia ALL 69 AML CLL CML Lymphoma Hodgkin lymphoma 281 Myeloma NHL aggressive NHL indolent NHL NOS T/NK cell NHL plasma cell dyscrasias Other haematology MDS 63 MPD 192

10 Leukaemia (ALL) ICD10: C91.0, C91.5, C91.8

11 Leukaemia (AML) ICD10: C92.0, C92.3-C92.6, C92.8, C93, C93.0, C93.7, C93.9, C94.0, C94.2-C94.4, C96.2, C96.4, C96.8

12 Leukaemia (CLL) ICD10: C91.1

13 Leukaemia (CML) ICD10: C92.1

14 Lymphoma (Hodgkin lymphoma) ICD10: C81, C81.0-C81.4, C81.7, C81.9

15 Lymphoma (NHL aggressive) ICD10: C82.4, C83.1, C83.3, C83.5, C83.7, C84.6, C84.7, C85.2

16 Lymphoma (NHL indolent) ICD10: C82, C82.0-C82.3, C82.6, C82.7, C82.9, C83.0, C88.0, C88.4, C91.3, C91.4, C91.6, C91.7, C91.9

17 Lymphoma (NHL NOS) ICD10: C82.5, C83, C83.8, C83.9, C85, C85.1, C85.7, C85.9, C88, C88.2, C88.3, C88.7, C88.9

18 Lymphoma (T/NK cell NHL) ICD10: C84, C84.0, C84.1, C84.4, C84.5, C84.8, C84.9, C86, C86.0-C86.6

19 Myeloma (plasma cell dyscrasias) ICD10: C90, C90.0-C90.3, D47.2, E85

20 Other haematology (MDS) ICD10: C92.2, C93.1, C93.3, C94.6, D46, D46.0-D46.2, D46.4-D46.7, D46.9

21 Other haematology (MPD) ICD10: D45, D47.1, D47.3-D47.5

22 helpdesk

What do blood cancer patients want? (And what do we need and expect too?)

What do blood cancer patients want? (And what do we need and expect too?) What do blood cancer patients want? (And what do we need and expect too?) John Reeve, Consumer Rep Haem. Onc. CSG Richard Stephens, Patient Member, NCIN Haematology SSCRG Delivering clinical research to

More information

Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand

Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand This list provides indications for the majority of adult BMTs that are performed in New Zealand. A small number of BMTs

More information

NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May Status (G / A / R) Status (G / A / R)

NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May Status (G / A / R) Status (G / A / R) Item 18-13c NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May 2013 BREAST CANCER MCN: Breast Disease: Breast Document ready to circulate lead to be discussed

More information

Cancer Outcomes and Services Dataset: Implications for clinical teams

Cancer Outcomes and Services Dataset: Implications for clinical teams Cancer Outcomes and Services Dataset: Implications for clinical teams Mick Peake Clinical Lead, NCIN National Clinical Lead, NHS Cancer Improvement Consultant & Senior Lecturer in Respiratory Medicine,

More information

Future Direction for Cancer Registries

Future Direction for Cancer Registries Future Direction for Cancer Registries Sally Vernon Head of Quality and Analysis Eastern Cancer Registry and Information Centre sally.vernon@ecric.nhs.uk In Ye Olde Days. 8 regional cancer registries Variation

More information

Haematological malignancies in England Cancers Diagnosed Haematological malignancies in England Cancers Diagnosed

Haematological malignancies in England Cancers Diagnosed Haematological malignancies in England Cancers Diagnosed Northern and Yorkshire Cancer Registry and Information Service Haematological malignancies in England Cancers Diagnosed 2001-2008 Haematological 2001-2008 Malignancies www.nycris.nhs.uk www.nycris.nhs.uk

More information

COSD & Source of Referral

COSD & Source of Referral COSD & Source of Referral A Brief guide October 2014 Michael Sharpe Data Improvement Manager National Cancer Registration Service What is COSD? Cancer and Outcomes Services Dataset Clinical dataset for

More information

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY Page 1 Rituximab INITIAL APPLICATION - Post-transplant The patient has B-cell post-transplant lymphoproliferative disder* To be used f a maximum of 8 treatment cycles Indications marked with * are Unapproved

More information

CLIC Sargent Eligibility Criteria

CLIC Sargent Eligibility Criteria 1 Eligibility Criteria DOCUMENT GOVERNANCE: Eligibility criteria Produced by J. Hawkins & Grants Team Sponsored by Dara de Burca Version Approval by Executive Team 10 th June 2014 Board of Trustees 3 rd

More information

National Cancer Intelligence Network Trends in incidence and outcome for haematological cancers in England:

National Cancer Intelligence Network Trends in incidence and outcome for haematological cancers in England: National Cancer Intelligence Network Trends in incidence and outcome for haematological cancers in England: 2001-2010 Trends in incidence and outcome for haematological cancers in England: 2001-2010 About

More information

Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation. December Reference : NHSCB/B4/a/1

Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation. December Reference : NHSCB/B4/a/1 Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation December 2012 Reference : NHSCB/B4/a/1 NHS Commissioning Board Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation

More information

to improve the collection and publication of data on chemotherapy activity, outcomes and costs, the chemotherapy dataset will be introduced

to improve the collection and publication of data on chemotherapy activity, outcomes and costs, the chemotherapy dataset will be introduced 6.19... to improve the collection and publication of data on chemotherapy activity, outcomes and costs, the chemotherapy dataset will be introduced in April 2012 and this should provide commissioners,

More information

Waiting Times for Suspected and Diagnosed Cancer Patients

Waiting Times for Suspected and Diagnosed Cancer Patients Waiting Times for Suspected and Diagnosed Cancer Patients 2015-16 Annual Report Waiting Times for Suspected and Diagnosed Cancer Patients 1 Waiting Times for Suspected and Diagnosed Cancer Patients Prepared

More information

Identifying and counting people living with treatable but not curable cancer

Identifying and counting people living with treatable but not curable cancer Identifying and counting people living with treatable but not curable cancer Rachel White Joanna Pethick, Archie Macnair, Gregory Fallica, Jennifer Than and Jane Maher September 2018 Who are the people

More information

Elements for a Public Summary

Elements for a Public Summary VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Chronic lymphocytic leukaemia 1 Chronic lymphocytic leukemia (CLL) is a condition characterized by a progressive accumulation

More information

Head and Neck Cancers Data Quality Report Radiotherapy and Chemotherapy Data

Head and Neck Cancers Data Quality Report Radiotherapy and Chemotherapy Data Head and Neck Cancers Data Quality Report Radiotherapy and Chemotherapy Data 1 This report has been compiled by Jinan Ridha, Analyst, Oxford Cancer Intelligence Unit (OCIU) With acknowledgements Mr Richard

More information

National Cancer Registration and Analysis Service Short Report: Chemotherapy, Radiotherapy and Surgical Tumour Resections in England: (V2)

National Cancer Registration and Analysis Service Short Report: Chemotherapy, Radiotherapy and Surgical Tumour Resections in England: (V2) National Cancer Registration and Analysis Service Short Report: Chemotherapy, Radiotherapy and Surgical Tumour Resections in England: 13-14 (V2) Produced as part of the Cancer Research UK - Public Health

More information

Table 2.1. Cohort studies of ethylene oxide and lymphohaematopoeitic cancer

Table 2.1. Cohort studies of ethylene oxide and lymphohaematopoeitic cancer Table.. Cohort studies of ethylene oxide and lymphohaematopoeitic cancer Hogstedt et al. (979a, 98), Sweden 89 operators with regular exposure to ethylene oxide and 78 maintenance staff with intermittent

More information

Reference: NHS England 1605

Reference: NHS England 1605 Clinical Commissioning Policy Proposition: Bendamustine with rituximab for first line treatment of advanced indolent non- Hodgkin s lymphoma (all ages) Reference: NHS England 1605 First published: TBC

More information

31 countries (117 registries, 20 national) Increased coverage in countries with regional registries 50% European population Overall >20 million

31 countries (117 registries, 20 national) Increased coverage in countries with regional registries 50% European population Overall >20 million 31 countries (117 registries, 20 national) Increased coverage in countries with regional registries 50% European population Overall >20 million cancer cases Adult patients (age 15+) 45 major cancer sites

More information

Consultation on publication of new cancer waiting times statistics Summary Feedback Report

Consultation on publication of new cancer waiting times statistics Summary Feedback Report Consultation on publication of new cancer waiting times statistics Summary Feedback Report Information Services Division (ISD) NHS National Services Scotland March 2010 An electronic version of this document

More information

An Introduction to Bone Marrow Transplant

An Introduction to Bone Marrow Transplant Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,

More information

Hematologic Malignancies 2013 Retrospective Study at Truman Medical Center

Hematologic Malignancies 2013 Retrospective Study at Truman Medical Center Hematologic Malignancies 2013 Retrospective Study at Truman Medical Center Kristen Strasser, MD & Abdulraheem Qasem, MD Introduction: Hematologic Malignancies includes malignant diseases of the bone marrow

More information

Allied Healthcare Professionals Module

Allied Healthcare Professionals Module Allied Healthcare Professionals Module Allied health professionals (AHPs) are key members of today s multidisciplinary healthcare team. They work in partnership with health and social care colleagues across

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Henson KE, Brock R, Charnock J, Wickramasinghe B, Will O, Pitman A. Risk of suicide after cancer diagnosis in England. JAMA Psychiatry. Published online November 21, 2018.

More information

VI.2 Elements for a public summary

VI.2 Elements for a public summary VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Leukaemia is a cancer that starts in the blood-forming cells of the bone marrow. Chronic lymphocytic leukaemia (CLL) is a type

More information

Cancer in Ireland with estimates for

Cancer in Ireland with estimates for Cancer in Ireland 1994-2015 with estimates for 2015-2017: Annual Report of the National Cancer Registry 2017 Page ABBREVIATIONS 95% CI 95% confidence interval APC Annual percentage change ASR Age-standardised

More information

Roche to present new clinical data across a variety of blood diseases at American Society of Hematology 2015 Annual Meeting

Roche to present new clinical data across a variety of blood diseases at American Society of Hematology 2015 Annual Meeting Media Release Basel, 5 November 2015 Roche to present new clinical data across a variety of blood diseases at American Society of Hematology 2015 Annual Meeting Gazyva/Gazyvaro (obinutuzumab) and investigational

More information

Subject Cancers in Firefighters and Fire Investigators

Subject Cancers in Firefighters and Fire Investigators If a full-time, part-time or volunteer firefighter or a fire investigator suffers from and is impaired by one of the prescribed s described below, and meets the conditions related to duration of employment

More information

2008 Oncology Pharmacy Preparatory Review Course Learning Objectives

2008 Oncology Pharmacy Preparatory Review Course Learning Objectives 2008 Oncology Pharmacy Preparatory Review Course Learning Objectives Session 1 Symptom Management, Part I, II & III Teresa A. Mays, Pharm D., BCOP Director, Investigational Drug Department San Antonio,

More information

National Cancer Drugs Fund List - Approved

National Cancer Drugs Fund List - Approved National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer

More information

An Overview of Blood and Marrow Transplantation

An Overview of Blood and Marrow Transplantation An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit

More information

Reducing the Door to Needle Time for Antibiotics in Suspected Neutropenic Sepsis using a Dedicated Clinical Pathway

Reducing the Door to Needle Time for Antibiotics in Suspected Neutropenic Sepsis using a Dedicated Clinical Pathway Reducing the Door to Needle Time for Antibiotics in Suspected Neutropenic Sepsis using a Dedicated Clinical Pathway Dr Alex Williams, Oncology Specialty Doctor. Cheltenham General Hospital Oncology Centre

More information

Comparing outcome between Belgian haematopoietic stem cell transplant centres

Comparing outcome between Belgian haematopoietic stem cell transplant centres ENCR2016, 2014/06/10 1 Comparing outcome between Belgian haematopoietic stem cell transplant centres Gilles Macq 1, Evelien Vaes 1, Geert Silversmit 1, Marijke Vanspauwen 1, Liesbet Van Eycken 1 & Yves

More information

Comparison of ProZES and IREP

Comparison of ProZES and IREP Department of Radiation Sciences, Institute of Radiation Protection Research Group Radiation risk Comparison of ProZES and IREP Alexander Ulanovsky, Elena Shemiakina Appendix 3 of the final ProZES report

More information

Understanding lymphoma: the importance of patient data

Understanding lymphoma: the importance of patient data Understanding lymphoma: the importance of patient data Introduction what is a cancer registry and why is it important? Cancer registries collect detailed, personalised information and data about cancer

More information

CANCER IN IRELAND with estimates for : ANNUAL REPORT OF THE NATIONAL CANCER REGISTRY

CANCER IN IRELAND with estimates for : ANNUAL REPORT OF THE NATIONAL CANCER REGISTRY CANCER IN IRELAND 1994-2016 with estimates for 2016-2018: ANNUAL REPORT OF THE NATIONAL CANCER REGISTRY 2018 ABBREVIATIONS 95% CI 95% confidence interval APC Annual percentage change ASR Age-standardised

More information

2010 Oncology Pharmacy Preparatory Review Course for Home Study Learning Objectives

2010 Oncology Pharmacy Preparatory Review Course for Home Study Learning Objectives 2010 Oncology Pharmacy Preparatory Review Course for Home Study Learning Objectives Acute Leukemia/Tumor Lysis Syndrome John M. Valgus, Pharm.D., BCOP Hematology/Oncology Specialist University of North

More information

Blood Cancers in the Community

Blood Cancers in the Community Over to you, mate Blood Cancers in the Community National Rural Health Conference NZ Rural General Practice Network April 7, 2018 Brian Grainger Haematology Registrar Auckland Acknowledgements Dr James

More information

What s a Transplant? What s not?

What s a Transplant? What s not? What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence

More information

CANCER INCIDENCE AND SURVIVAL STATISTICS FOR NORTHERN IRELAND

CANCER INCIDENCE AND SURVIVAL STATISTICS FOR NORTHERN IRELAND 12 March 2019 CANCER INCIDENCE AND SURVIVAL STATISTICS FOR NORTHERN IRELAND 1993-2017 Official Statistics on cancers diagnosed in Northern Ireland during 1993-2017 were published today. This release provides

More information

GUIDELINE FOR THE MANAGEMENT AND PREVENTION OF ACUTE TUMOUR LYSIS SYNDROME IN HAEMATOLOGICAL MALIGNANCIES

GUIDELINE FOR THE MANAGEMENT AND PREVENTION OF ACUTE TUMOUR LYSIS SYNDROME IN HAEMATOLOGICAL MALIGNANCIES GUIDELINE FOR THE MANAGEMENT AND PREVENTION OF ACUTE TUMOUR LYSIS SYNDROME IN HAEMATOLOGICAL MALIGNANCIES Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target

More information

North of Scotland Cancer Network Clinical Management Guideline for Metastatic Malignancy of Undefined Primary Origin (MUO)

North of Scotland Cancer Network Clinical Management Guideline for Metastatic Malignancy of Undefined Primary Origin (MUO) North of Scotland Cancer Network Clinical Management Guideline for Metastatic Malignancy of Undefined Primary Origin (MUO) UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Original Prepared by NMcL April 2016

More information

Clinical commissioning policy: Bendamustine with rituximab for first line treatment of advanced indolent non-hodgkin s lymphoma (all ages)

Clinical commissioning policy: Bendamustine with rituximab for first line treatment of advanced indolent non-hodgkin s lymphoma (all ages) Clinical commissioning policy: Bendamustine with rituximab for first line treatment of advanced indolent non-hodgkin s lymphoma (all ages) NHS England Reference: 170055P 1 NHS England INFORMATION READER

More information

Frequency of non specific morphology codes (ICD O M) within the National Cancer Data Repository ( ) for cancer in Teenagers and Young Adults

Frequency of non specific morphology codes (ICD O M) within the National Cancer Data Repository ( ) for cancer in Teenagers and Young Adults Frequency of non specific morphology codes (ICD O M) within the National Cancer Data Repository (2007 09) for cancer in Teenagers and Young Adults (TYA) CTYA SSCRG Data quality report on the frequency

More information

Pathways to diagnosis of haematological malignancies

Pathways to diagnosis of haematological malignancies Pathways to diagnosis of haematological malignancies Debra Howell Epidemiology and Cancer Statistics Group Health Sciences, University of York (debra.howell@york.ac.uk) haematological malignancy research

More information

Clinical Policy: Donor Lymphocyte Infusion

Clinical Policy: Donor Lymphocyte Infusion Clinical Policy: Reference Number: PA.CP.MP.101 Effective Date: 01/18 Last Review Date: 11/16 Coding Implications Revision Log This policy describes the medical necessity requirements for a donor lymphocyte

More information

Table Cohort studies of consumption of alcoholic beverages and cancers of the lymphatic and haematopoietic system in the general population

Table Cohort studies of consumption of alcoholic beverages and cancers of the lymphatic and haematopoietic system in the general population categories Lim et al., (2007), USA, The National Institutes of Health-former American Association of Retired Persons (NIH- AARP) Diet and Health Study 473984 participants with correct questionnaire and

More information

Cancer in Ireland : Annual Report of the National Cancer Registry

Cancer in Ireland : Annual Report of the National Cancer Registry Cancer in Ireland 1-: Annual Report of the National Cancer Registry ABBREVIATIONS % CI % confidence interval APC Annual percentage change ASR Age-standardised rate (European standard population) CNS Central

More information

Systematic Reviews in Hematological Malignancies

Systematic Reviews in Hematological Malignancies Systematic Reviews in Hematological Malignancies Pia Raanani, MD Davidoff Cancer Center Rabin Medical Center, Israel 1 2 Disorder CHMG Systematic review* Title Protocol Full Review Myelodysplastic syndrome

More information

SACT: What can we learn from Real World Data? Dr Rebecca Smittenaar Analytical Lead (Systemic Anti-Cancer Therapy) Public Health England

SACT: What can we learn from Real World Data? Dr Rebecca Smittenaar Analytical Lead (Systemic Anti-Cancer Therapy) Public Health England SACT: What can we learn from Real World Data? Dr Rebecca Smittenaar Analytical Lead (Systemic Anti-Cancer Therapy) Public Health England What will I cover? Brief introduction to the SACT database What

More information

Faster Cancer Treatment Indicators: Use cases

Faster Cancer Treatment Indicators: Use cases Faster Cancer Treatment Indicators: Use cases 2014 Date: October 2014 Version: Owner: Status: v01 Ministry of Health Cancer Services Final Citation: Ministry of Health. 2014. Faster Cancer Treatment Indicators:

More information

Dorset Cancer Alliance:

Dorset Cancer Alliance: Dorset Cancer Alliance: - Structure and Functions - SSG specification Where are we without a Network? Wessex Strategic Cancer Network Individual Trust Cancer Services Dorset CCG Specialised Commissioning

More information

2007 Workshop of Society for Hematopathology & European Association for Hematopathology Indianapolis, IN, USA Case # 228

2007 Workshop of Society for Hematopathology & European Association for Hematopathology Indianapolis, IN, USA Case # 228 2007 Workshop of Society for Hematopathology & European Association for Hematopathology Indianapolis, IN, USA Case # 228 Vishnu V. B Reddy, MD University of Alabama at Birmingham Birmingham, AL USA 11/03/07

More information

Improving Outcomes in Haematological Cancers

Improving Outcomes in Haematological Cancers NHS National Institute for Clinical Excellence Guidance on Cancer Services Improving Outcomes in Haematological Cancers The Manual Haematological cancers service guidance Cancer service guidance supports

More information

Information Services Division NHS National Services Scotland

Information Services Division NHS National Services Scotland Cancer in Scotland April 2017 First published in June 2004, revised with each National Statistics publication Next due for revision October 2017 Information Services Division NHS National Services Scotland

More information

Advances in Immunotherapy for Lymphoma. Ashley Freeman, MD, FRCPC Immunotherapy Research Fellow

Advances in Immunotherapy for Lymphoma. Ashley Freeman, MD, FRCPC Immunotherapy Research Fellow Advances in Immunotherapy for Lymphoma Ashley Freeman, MD, FRCPC Immunotherapy Research Fellow The immune system and cancer Immunotherapies available for lymphoma Upcoming immunotherapy clinical trials

More information

Scottish Cancer Taskforce: National Cancer Quality Steering Group Cancer Clinical Audit

Scottish Cancer Taskforce: National Cancer Quality Steering Group Cancer Clinical Audit Scottish Cancer Taskforce: National Cancer Quality Steering Group Cancer Clinical Audit National Cancer Clinical Audit: Baseline Survey Report (May 09) Purpose: The purpose of this paper is to provide

More information

Macmillan Publications

Macmillan Publications S1 S2 S3 S3 S3 S4 S5 S6 S7 S8 S8 S9 S10 S11 S11 S12 S13 S14 S15 S17 S18 S19 Bladder Cancer: Non-Invasive, Invasive and Advanced Bone Cancer: Primary, Secondary Colon Cancer, Anal Cancer, Rectal Cancer

More information

Leukocytosis - Some Learning Points

Leukocytosis - Some Learning Points Leukocytosis - Some Learning Points Koh Liang Piu Department of Hematology-Oncology National University Cancer Institute National University Health System Objectives of this talk: 1. To provide some useful

More information

Cancer-specific variation in emergency presentation by sex, age and deprivation across 27 common and rarer cancers

Cancer-specific variation in emergency presentation by sex, age and deprivation across 27 common and rarer cancers Cancer-specific variation in emergency presentation by sex, age and deprivation across 27 common and rarer cancers Gary Abel, Jon Shelton, Sam Johnson, Lucy Elliss-Brookes, Yoryos Lyratzopoulos Why worry

More information

2010 National Survey. East Kent Hospitals University NHS Trust

2010 National Survey. East Kent Hospitals University NHS Trust National Cancer Patient Experience Programme 2010 National Survey Published January 2011 The National Cancer Patient Experience Survey Programme is being undertaken by Quality Health on behalf of the Department

More information

2010 National Survey. The North West London Hospitals NHS Trust

2010 National Survey. The North West London Hospitals NHS Trust National Cancer Patient Experience Programme 2010 National Survey Published January 2011 The National Cancer Patient Experience Survey Programme is being undertaken by Quality Health on behalf of the Department

More information

2010 National Survey. Royal National Orthopaedic Hospital NHS Trust

2010 National Survey. Royal National Orthopaedic Hospital NHS Trust National Cancer Patient Experience Programme 2010 National Survey Published January 2011 The National Cancer Patient Experience Survey Programme is being undertaken by Quality Health on behalf of the Department

More information

2010 National Survey. The Leeds Teaching Hospitals NHS Trust

2010 National Survey. The Leeds Teaching Hospitals NHS Trust National Cancer Patient Experience Programme 2010 National Survey Published January 2011 The National Cancer Patient Experience Survey Programme is being undertaken by Quality Health on behalf of the Department

More information

Clinical Commissioning Policy: Bendamustine with rituximab for relapsed and refractory mantle cell lymphoma (all ages)

Clinical Commissioning Policy: Bendamustine with rituximab for relapsed and refractory mantle cell lymphoma (all ages) Clinical Commissioning Policy: Bendamustine with rituximab for relapsed and refractory mantle cell lymphoma (all ages) NHS England Reference: 170029P 1 NHS England INFORMATION READER BOX Directorate Medical

More information

Trial no. Status Phase Treatment Pre-conditioning Primary endpoints Secondary endpoints Diagnosis Sponsor

Trial no. Status Phase Treatment Pre-conditioning Primary endpoints Secondary endpoints Diagnosis Sponsor Supplemental table 1. Overview of recent clinical phase I and II trials assessing the safety and efficacy of TCR-modified T cells in cancer patients as registered at clinicaltrials.gov by September 1,

More information

2010 National Survey. University College London Hospitals NHS Foundation Trust

2010 National Survey. University College London Hospitals NHS Foundation Trust National Cancer Patient Experience Programme 2010 National Survey University College London Hospitals NHS Foundation Trust Published January 2011 The National Cancer Patient Experience Survey Programme

More information

H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS

H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS Each of you should have 37 new cards: 7 orange cards for antimetabolites 11 white cards for miscellaneous drugs (2 DNA synthesis inhibitors, 1 enzyme,

More information

Cancer Survival in Wales, Goroesi Cancr yng Nghymru,

Cancer Survival in Wales, Goroesi Cancr yng Nghymru, Cancer Survival in Wales, 1989-1998 Goroesi Cancr yng Nghymru, 1989-1998 Welsh Cancer Intelligence & Surveillance Unit Uned Arolygiaeth a Gwybodaeth Cancr Cymru DIRECTOR S INTRODUCTION I am pleased to

More information

2010 National Survey. Northern Lincolnshire and Goole Hospitals NHS Foundation Trust

2010 National Survey. Northern Lincolnshire and Goole Hospitals NHS Foundation Trust National Cancer Patient Experience Programme 2010 National Survey Northern Lincolnshire and Goole Hospitals NHS Foundation Trust Published January 2011 The National Cancer Patient Experience Survey Programme

More information

The Future of the Peer Review Programme

The Future of the Peer Review Programme The Future of the Peer Review Programme The future of the programme has been in some considerable doubt. However thanks to the support of: Sean Duffy National Clinical Lead for Cancer, James Palmer Clinical

More information

Leukemias And Lymphomas (Contemporary Issues In Clinical Oncology Vol 4)

Leukemias And Lymphomas (Contemporary Issues In Clinical Oncology Vol 4) Leukemias And Lymphomas (Contemporary Issues In Clinical Oncology Vol 4) If you are looking for the book Leukemias and Lymphomas (Contemporary Issues in Clinical Oncology Vol 4) in pdf form, in that case

More information

CRN SWP Business Intelligence Unit

CRN SWP Business Intelligence Unit CRN SWP Business Intelligence Unit Name of report: Cancer Update Q3 2017/2018 Release date: 26 th February 2018 Data source(s) used: Portfolio ODP Data cut-off: 1 st January 2018 Brief Summary: Summary

More information

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on

More information

FAQs- Janet s Inbox. Janet Brunner, PA-C Wed. Feb. 26, 2014 TRAINING & DEVELOPMENT 1.

FAQs- Janet s Inbox. Janet Brunner, PA-C Wed. Feb. 26, 2014 TRAINING & DEVELOPMENT 1. FAQs- Janet s Inbox Janet Brunner, PA-C Wed. Feb. 26, 2014 TRAINING & DEVELOPMENT 1. Disclosures I have no relevant conflicts of interest to disclose. TRAINING & DEVELOPMENT 2. Objectives 1. Determine

More information

Wales Cancer Patient Experience Survey Hywel Dda University Health Board. Published January 2014

Wales Cancer Patient Experience Survey Hywel Dda University Health Board. Published January 2014 Wales Cancer Patient Experience Survey 2013 Hywel Dda University Health Published January 2014 The Wales Cancer Patient Experience Survey was undertaken by Quality Health on behalf of the Welsh Government

More information

Incidence-based Mortality Method to Partition Tumor-Specific Mortality Trends: Application to Non-Hodgkin Lymphoma Cancer

Incidence-based Mortality Method to Partition Tumor-Specific Mortality Trends: Application to Non-Hodgkin Lymphoma Cancer Incidence-based Mortality Method to Partition Tumor-Specific Mortality Trends: Application to Non-Hodgkin Lymphoma Cancer Nadia Howlader, Lindsay M Morton, Eric J Feuer, Caroline Besson, Eric A Engels

More information

Aviva Group Protection Our guide to cancer

Aviva Group Protection Our guide to cancer ww For employers use only. Aviva Group Protection Our guide to cancer 1 2 In 2013, 131 million working days were lost due to sickness absence in the UK, at an average of 4.4 working days per employee 1.

More information

Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies

Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies UNCONTROLLED WHEN PRINTED Note: NOSCAN Haematology MCN has approved the information contained within this document to guide

More information

13-24 year olds with cancer in England Incidence, mortality and survival

13-24 year olds with cancer in England Incidence, mortality and survival 13-24 year olds with cancer in England Incidence, mortality and survival National Cancer Registration and Analysis Service in collaboration with Teenage Cancer Trust About Public Health England Public

More information

National Cancer Patient Experience Programme National Survey. South Tees Hospitals NHS Foundation Trust. Published September 2014

National Cancer Patient Experience Programme National Survey. South Tees Hospitals NHS Foundation Trust. Published September 2014 National Cancer Patient Experience Programme 2014 National Survey South Tees Hospitals NHS Foundation Trust Published September 2014 The National Cancer Patient Experience Survey Programme is undertaken

More information

ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER

ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/384641/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER The Paediatric

More information

National Cancer Patient Experience Survey 2016 Technical Documentation July 2017

National Cancer Patient Experience Survey 2016 Technical Documentation July 2017 National Cancer Patient Experience Survey 2016 Technical Documentation July 2017 1 Contents 1. Introduction 2. Scoring 3. Significance Tests (for national data) 4. Case-mix Adjustment (for local data)

More information

National Cancer Patient Experience Programme. 2012/13 National Survey. East Kent Hospitals University NHS Foundation Trust. Published August 2013

National Cancer Patient Experience Programme. 2012/13 National Survey. East Kent Hospitals University NHS Foundation Trust. Published August 2013 National Cancer Patient Experience Programme 2012/13 National Survey Published August 2013 The National Cancer Patient Experience Survey Programme is being undertaken by Quality Health on behalf of NHS

More information

National Cancer Patient Experience Programme. 2012/13 National Survey. James Paget University Hospitals NHS Foundation Trust. Published August 2013

National Cancer Patient Experience Programme. 2012/13 National Survey. James Paget University Hospitals NHS Foundation Trust. Published August 2013 National Cancer Patient Experience Programme 2012/13 National Survey Published August 2013 The National Cancer Patient Experience Survey Programme is being undertaken by Quality Health on behalf of NHS

More information

Lymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC

Lymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC Lymphoma: What You Need to Know Richard van der Jagt MD, FRCPC Overview Concepts, classification, biology Epidemiology Clinical presentation Diagnosis Staging Three important types of lymphoma Conceptualizing

More information

National Cancer Patient Experience Programme. 2012/13 National Survey. Milton Keynes Hospital NHS Foundation Trust. Published August 2013

National Cancer Patient Experience Programme. 2012/13 National Survey. Milton Keynes Hospital NHS Foundation Trust. Published August 2013 National Cancer Patient Experience Programme 2012/13 National Survey Published August 2013 The National Cancer Patient Experience Survey Programme is being undertaken by Quality Health on behalf of NHS

More information

Clinical Commissioning Policy: Bendamustine with rituximab for relapsed and refractory mantle cell lymphoma (all ages) NHS England Reference: P

Clinical Commissioning Policy: Bendamustine with rituximab for relapsed and refractory mantle cell lymphoma (all ages) NHS England Reference: P Clinical Commissioning Policy: Bendamustine with rituximab for relapsed and refractory mantle cell lymphoma (all ages) NHS England Reference: 170054P 1 NHS England INFORMATION READER BOX Directorate Medical

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

ALL CANCER (EXCLUDING NMSC)

ALL CANCER (EXCLUDING NMSC) ALL CANCER (EXCLUDING NMSC) AVERAGE NUMBER OF CASES PER YEAR (2011-2015) AVERAGE NUMBER OF DEATHS PER YEAR (2011-2015) Male Female Both sexes Male Female Both sexes 4,557 4,516 9,073 1 2,196 1,984 4,180

More information

BLOOD AND LYMPH CANCERS

BLOOD AND LYMPH CANCERS BLOOD AND LYMPH CANCERS 2 Blood and Lymph Cancers Highlights from the 2009 Annual Meeting of the American Society of Clinical Oncology Edited by Kenneth C. Anderson, MD Harvard Medical School and Dana-Farber

More information

Pattern of deaths in the year following diagnosis in cancer patients aged years in England. Children and Young Adults CRG

Pattern of deaths in the year following diagnosis in cancer patients aged years in England. Children and Young Adults CRG Pattern of deaths in the year following diagnosis in cancer patients aged 15-24 years in England Children and Young Adults CRG Pattern of deaths in the year following diagnosis in cancer patients aged

More information

Module Guide 2017/18

Module Guide 2017/18 MSc in Oncology Including PG Certificate and PG Diploma Cancer Treatments 2 Module Guide 2017/18 Part B Clinical Sciences Contents Module details 1.1 Module overview... 3 1.2 Module specification... 3

More information

REPORT ON PROSPECTIVE AUDIT OF LYMPHOMA PATIENTS BORDERS, FIFE, AND LOTHIAN DIAGNOSED IN 2008

REPORT ON PROSPECTIVE AUDIT OF LYMPHOMA PATIENTS BORDERS, FIFE, AND LOTHIAN DIAGNOSED IN 2008 SE Scotland Cancer Network SCAN AUDIT REPORT ON PROSPECTIVE AUDIT OF LYMPHOMA PATIENTS BORDERS, FIFE, AND LOTHIAN DIAGNOSED IN 2008 Reports prepared by: Christine Maguire SCAN Cancer Audit Facilitator

More information

Q&A Session Collecting Cancer Data: Hematopoietic and Lymphoid Neoplasms Thursday, November 6, 2014

Q&A Session Collecting Cancer Data: Hematopoietic and Lymphoid Neoplasms Thursday, November 6, 2014 Q&A Session Collecting Cancer Data: Hematopoietic and Lymphoid Neoplasms Thursday, November 6, 2014 Q: If polycythemia ruba vera (PRV) or essential thrombocythemia (ET) is diagnosed by peripheral smear,

More information

Donor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant

Donor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant Last Review Status/Date: September 2014 Page: 1 of 8 Malignancies Treated with an Allogeneic Description Donor lymphocyte infusion (DLI), also called donor leukocyte or buffy-coat infusion is a type of

More information

Information Services Division NHS National Services Scotland

Information Services Division NHS National Services Scotland Cancer in Scotland October 2012 First published in June 2004, revised with each National Statistics publication Next due for revision April 2013 Information Services Division NHS National Services Scotland

More information